Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
PRIMARY OBJECTIVE:
I. To determine if the time to local failure is improved with FSRS compared to SRS in patients with intact (i.e., unresected) brain metastases.
SECONDARY OBJECTIVES:
I. To compare time to intracranial progression-free survival between FSRS and SRS.
II. To compare overall survival between FSRS and SRS. III. To determine if the time to local failure is improved with FSRS compared to SRS, as evaluated by central review of imaging.
IV. To evaluate if there is any difference in central nervous system (CNS) failure patterns (local versus [vs.] distant brain failure vs. both) in patients who receive FSRS compared to patients who receive SRS.
V. To compare the rates of radiation necrosis in patients who receive FSRS vs. SRS.
VI. To compare the time to salvage whole brain radiation therapy (WBRT) between patients who receive FSRS and those who receive SRS.
VII. To compare the rates of post-treatment adverse events associated with FSRS and SRS.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo SRS over 30-90 minutes for 1 fraction on study. Additionally, patients undergo computed tomography (CT) and magnetic resonance imaging (MRI) on study.
ARM II: Patients undergo FSRS over 30-90 minutes for 3 fractions on study. Additionally, patients undergo CT and MRI on study.
After completion of study treatment, patients are followed up every 3 months for 1 year, every 4 months for 1 year then every 6 months for 3 years.
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of one of the following solid tumor malignancies within 5 years prior to registration:
Patients must have at least 1 and up to 8 total intact brain metastases detected on a contrast-enhanced MRI performed ≤ 21 days prior to registration
At least 1 of the up to 8 lesions must be a study eligible lesion, defined as lesion with a maximum diameter as measured on any orthogonal plane (axial, sagittal, coronal) of ≥ 1.0 cm and ≤ 3.0 cm
All brain metastases must be located outside of the brainstem and ≥ 5 mm from the optic nerves or optic chiasm and ≤ 3.0 cm in maximum dimension
Patients must have a diagnosis-specific graded prognostic assessment ≥ 1.5
No more than 2 lesions planned for resection if clinically indicated
No known leptomeningeal disease (LMD)
Age ≥ 18 years
Karnofsky performance status (KPS) ≥ 60
Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal
No prior radiotherapy to the brain (partial or whole brain irradiation, SRS, FSRS, or prophylactic cranial irradiation [PCI])
New York Heart Association Functional Classification II or better (NYHA Functional Classification III/IV are not eligible) (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification)
No active infection currently requiring intravenous (IV) antibiotic management
No hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
No chronic obstructive pulmonary disease exacerbation or other acute respiratory illness precluding study therapy
Tucson, Arizona 85719, United States
UACC-IIT@uacc.arizona.edu
Irvine, California 92612, United States
Orange, California 92868, United States
New Britain, Connecticut 06050, United States
Aventura, Florida 33180, United States
Coral Gables, Florida 33146, United States
Deerfield Beach, Florida 33442, United States
Miami, Florida 33136, United States
Plantation, Florida 33324, United States
Overland Park, Kansas 66210, United States
Louisville, Kentucky 40202, United States
Columbia, Maryland 21044, United States
Easton, Maryland 21601, United States
Glen Burnie, Maryland 21061, United States
Westminster, Maryland 21157, United States
Ann Arbor, Michigan 48106, United States
Brighton, Michigan 48114, United States
Brownstown, Michigan 48183, United States
CTOResearch@hfhs.org313-916-3721
Clinton Township, Michigan 48038, United States
Ypsilanti, Michigan 48197, United States
Maple Grove, Minnesota 55369, United States
City of Saint Peters, Missouri 63376, United States
Columbia, Missouri 65212, United States
Somerville, New Jersey 08876, United States
New York, New York 10016, United States
Syracuse, New York 13210, United States
Cincinnati, Ohio 45219, United States
West Chester, Ohio 45069, United States
Bethlehem, Pennsylvania 18015, United States
Philadelphia, Pennsylvania 19104, United States
Sioux Falls, South Dakota 57117-5134, United States
Houston, Texas 77030, United States
San Antonio, Texas 78229, United States
Salt Lake City, Utah 84112, United States
Burlington, Vermont 05405, United States
Vancouver, Washington 98684, United States
Madison, Wisconsin 53718, United States
Madison, Wisconsin 53792, United States
Montreal, Quebec H3H 2R9, Canada
UACC-IIT@uacc.arizona.edu
800-378-9373
501-686-8274
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
becomingapatient@coh.org626-256-4673
becomingapatient@coh.org800-826-4673
760-536-7700
ucstudy@uci.edu877-827-8839
877-467-3411
cancercto@ucsd.edu858-822-5354
becomingapatient@coh.org800-826-4673
clinical.trials@kp.org800-398-3996
Cancer.trial.info@cshs.org310-423-2133
707-521-3830
clinical.trials@kp.org800-398-3996
ucstudy@uci.edu877-827-8839
ccto-office@stanford.edu650-498-7061
rhabbaba@health.ucsd.edu
707-521-3830
becomingapatient@coh.org800-826-4673
877-467-3411
becomingapatient@coh.org800-826-4673
720-848-0650
719-365-2406
719-364-6700
970-297-6150
Roster@nrgoncology.org412-339-5294
Roster@nrgoncology.org412-339-5294
970-203-7083
954-461-2180
561-955-4800
305-243-2647
305-243-2647
kginnity@med.miami.edu
305-243-2647
786-596-2000
305-243-2647
305-243-2647
ClinicalTrials@moffitt.org800-679-0775
ClinicalTrials@moffitt.org800-679-0775
ClinicalTrials@moffitt.org800-679-0775
ClinicalTrials@moffitt.org800-679-0775
888-946-7447
ORS@piedmont.org404-425-7943
404-778-1868
404-851-7115
research@wellstar.org470-793-4071
research@wellstar.org470-793-4071
i.webster@hawaiicancercare.com808-524-6115
808-532-0315
808-545-8548
808-586-2979
808-531-8521
808-983-6090
808-535-7960
info@hawaiicancercare.com808-539-2273
rohta@queens.org
morganthaler.jodi@mhsil.com217-876-4762
cancer@northwestern.edu312-695-1301
Cancer_Studies@rush.edu312-226-2371
cancerclinicaltrials@bsd.uchicago.edu773-702-8222
Research@Carle.com800-446-5532
morganthaler.jodi@mhsil.com217-876-4762
morganthaler.jodi@mhsil.com217-876-4762
Research@carle.com800-446-5532
morganthaler.jodi@mhsil.com217-876-4762
Jrohde@emhc.org630-758-5460
Research@carle.com800-446-5532
708-226-4357
630-646-6075
cancerclinicaltrials@bsd.uchicago.edu773-702-8222
morganthaler.jodi@mhsil.com217-876-4762
morganthaler.jodi@mhsil.com217-876-4762
nctnprogram_rhlccc@northwestern.edu
cancerclinicaltrials@bsd.uchicago.edu773-702-8222
dschwab@wustl.edu314-747-9912
217-545-7929
800-444-7541
pallante.beth@mhsil.com217-528-7541
Research@carle.com800-446-5532
Donald.Smith3@nm.org630-352-5360
CancerResearch@powershealth.org219-836-6879
cancerclinicaltrials@bsd.uchicago.edu855-702-8222
219-924-8178
cccois@goshenhealth.com574-364-2973
219-947-1795
CancerResearch@COMHS.org219-836-6875
219-836-3349
mnicholson@comhs.org219-934-8869
CancerResearch@COMHS.org219-836-6875
515-956-4132
ksoder@mcfarlandclinic.com515-239-4734
800-237-1225
KUCC_Navigation@kumc.edu913-588-3671
OlatheCCResearch@kumc.edu913-588-1569
KUCC_Navigation@kumc.edu913-588-3671
270-706-5470
859-257-3379
502-562-3429
Roster@nrgoncology.org412-339-5294
ctoinfo@louisville.edu502-852-2755
vanissa.sorrels@owensborohealth.org270-691-8094
clinicalresearch@mainehealth.org207-396-8670
207-459-1600
clinicalresearch@mainehealth.org207-396-8670
info@mdproton.com410-369-5226
800-888-8823
410-601-9083
443-643-3010
443-546-1300
Christina.weisenborn@umm.edu410-822-1000
410-553-8100
Sarah.Larson@umm.edu301-755-4397
410-871-6400
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
CancerAnswerLine@med.umich.edu800-865-1125
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
CTOResearch@hfhs.org313-916-3721
CTOResearch@hfhs.org313-916-3721
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
kfife3@hfhs.org248-849-5332
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
CTOResearch@hfhs.org313-916-3721
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
612-624-2620
mmcorc@healthpartners.com952-993-1517
coborncancercenter@centracare.com877-229-4907
mmcorc@healthpartners.com952-993-1517
601-815-6700
info@siteman.wustl.edu800-600-3606
573-882-7440
info@siteman.wustl.edu800-600-3606
314-996-5569
417-269-4520
info@siteman.wustl.edu800-600-3606
info@siteman.wustl.edu800-600-3606
info@siteman.wustl.edu800-600-3606
unmcrsa@unmc.edu402-559-6941
402-559-5600
unmcrsa@unmc.edu402-559-6941
research@sncrf.org702-384-0013
212-639-7592
ONCTrialNow@jefferson.edu215-600-9151
joanne.loeb@rwjbh.org973-322-2934
212-639-7592
212-639-7592
732-776-4240
732-235-7356
732-235-7356
Christine.Kosmides@rwjbh.org973-926-7230
clinicaltrialsresearch@valleyhealth.com201-634-5792
clinicaltrialsresearch@valleyhealth.com201-634-5792
ONCTrialNow@jefferson.edu215-600-9151
Siby.Varughese@rwjbh.org908-685-2481
Lennette.Gonzales@rwjbh.org732-557-8294
HSC-ClinicalTrialInfo@salud.unm.edu505-925-0348
Adg9003@nyp.org718-780-3677
david.wallach@nyulangone.org646-754-4624
212-639-7592
Roster@nrgoncology.org412-339-5294
212-639-7592
516-734-8896
cancertrials@nyulangone.org212-263-4432
CCTO@mssm.edu212-824-7309
CancerTrials@nyulangone.org
CCTO@mssm.edu212-824-7309
CCTO@mssm.edu212-824-7309
212-434-4460
212-639-7592
212-746-1848
516-734-8896
crsu@mssm.edu212-824-7391
585-275-5830
800-862-2215
315-464-5476
315-464-5476
eskwak@montefiore.org718-379-6866
eskwak@montefiore.org718-379-6866
eskwak@montefiore.org718-379-6866
212-639-7592
OncologyClinicalTrialsFargo@sanfordhealth.org701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org701-234-6161
800-641-2422
clinical.trials@daytonncorp.org937-528-2900
cancer@uchealth.com513-584-7698
CTUReferral@UHhospitals.org800-641-2422
Jamesline@osumc.edu800-293-5066
Jennifer.Sexton@ohiohealth.com614-788-3860
Jennifer.Sexton@ohiohealth.com614-788-3860
Jennifer.Sexton@ohiohealth.com614-788-3860
Jennifer.Sexton@ohiohealth.com614-788-3860
clinical.trials@daytonncorp.org937-528-2900
CTUReferral@UHhospitals.org800-641-2422
cancer@uchealth.com513-584-7698
clinical.trials@daytonncorp.org937-528-2900
ou-clinical-trials@ouhsc.edu405-271-8777
CanRsrchStudies@providence.org503-215-2614
503-413-2150
cancer@lhs.org800-220-4937
CanRsrchStudies@providence.org503-215-2614
CanRsrchStudies@providence.org503-215-2614
503-413-1742
610-776-4714
484-503-4151
Roster@nrgoncology.org412-339-5294
888-808-6762
Roster@nrgoncology.org412-339-5294
CTO@hmc.psu.edu717-531-3779
rupeshk@baptisthealth.net786-999-4267
PMCancerResearch@pennmedicine.upenn.edu215-349-8245
ONCTrialNow@jefferson.edu215-600-9151
ONCTrialNow@jefferson.edu215-600-9151
412-647-2811
412-621-2334
610-776-4714
Roster@nrgoncology.org412-339-5294
610-988-9323
877-441-7957
877-441-7957
Heather_Rich@bshsi.org864-603-6234
Heather_Rich@bshsi.org864-603-6234
OncologyClinicTrialsSF@sanfordhealth.org605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org605-312-3320
800-811-8480
800-811-8480
askmdanderson@mdanderson.org866-632-6789
burton@bcm.edu713-798-1354
713-792-3245
askmdanderson@mdanderson.org866-632-6789
askmdanderson@mdanderson.org877-632-6789
askmdanderson@mdanderson.org877-632-6789
phoresearchoffice@uthscsa.edu210-450-3800
askmdanderson@mdanderson.org877-632-6789
rpo@uvm.edu802-656-4101
rpo@uvm.edu802-656-8990
uvacancertrials@hscmail.mcc.virginia.edu434-243-6303
CTOclinops@vcu.edu804-628-6430
research@valleymed.org425-228-3440
oncologyresearch@lhs.org
503-413-2150
Juli.Alford@aspirus.org715-623-9869
ResearchDept@thedacare.org920-364-3604
cancerctr@gundersenhealth.org608-775-2385
clinicaltrials@cancer.wisc.edu800-622-8922
clinicaltrials@cancer.wisc.edu800-622-8922
414-805-3666
Beth.Knetter@aspirus.org715-847-2353
Beth.Knetter@aspirus.org715-847-2353
877-405-6866
715-422-7718
info.cr.chum@ssss.gouv.qc.ca514-890-8000 ext. 12725
evelyn.ortega@muhc.mcgill.ca514-934-1934 ext. 48354
353 1 4065000
info@cancercontrol.ie353 1 8287100
353 21 4861100
353 21 4922324